Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Sponsor_160x130

Aptahem is supporting Sepsisfonden

GSA-320x260

Aptahem is supporting Global Sepsis Alliance and is part of the World Sepsis Declaration